Vitamin A Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Vitamin A Deficiency Market Outlook

Thelansis’s “Vitamin A Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vitamin A Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Vitamin A Deficiency Overview

Vitamin A is a lipid-soluble micronutrient that plays a vital role in cellular development, metabolism, immune function, vision, and reproductive processes. Insufficient intake or absorption of vitamin A can lead to a deficiency, impairing important physiological functions. Vitamin A deficiency (VAD) is a widespread health concern affecting young children and is associated with significant morbidity and mortality. According to the Institute of Medicine, the recommended dietary allowance (RDA) of vitamin A for healthy adults is 700 micrograms/day for women and 900 micrograms/day for men. Children, pregnant women, and lactating women have different RDAs, which are 300 to 900, 770, and 1300 micrograms/day, respectively. Ocular symptoms related to vitamin A deficiency have been observed to occur when blood concentrations are lower than 10 micrograms/dL. Inadequate nutrition compounded by chronic inflammation resulting from regular gastrointestinal (GI) infections is the primary cause of vitamin A deficiency. This situation often leads to multiple micronutrient deficiencies. Vitamin A is crucial for regenerating visual pigments, maintaining mucosal membranes, and proper immune function. Insufficient vitamin A levels can cause night blindness due to impaired regeneration of visual pigments in retinal rods. If the deficiency persists, the retinal rods will degenerate, leading to a condition called xerophthalmia, which can result in permanent blindness. Insufficient vitamin A also leads to dryness and breakdown of the mucosal membranes in the intestines and lungs, along with compromised immune function, resulting in frequent infections and anemia caused by chronic inflammation. The recommended treatment for vitamin A deficiency is vitamin A supplementation. The prognosis of vitamin A deficiency depends on the severity of the disease when treatment is initiated. Severe vitamin A deficiency may lead to irreversible vision loss or blindness, heightened susceptibility to infections, and impaired immune function, significantly increasing mortality rates.

• In the USA, vitamin A deficiency is rare and estimated to affect only 0.3% of individuals. Conversely, the prevalence of vitamin A toxicity in the US is much higher than that of deficiency.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: